LIPID In Vivo Transfection Reagent

Catalog # 5010 - 0.5 mL (10 injections)	$ 405
Catalog # 5011 - 1.5 mL (30 injections)	$ 895

In Vivo Transfection Reagent (LIPID-based)

siRNA and plasmid DNA in vivo delivery reagent

Modes of administration:

• Systemic intravenous (i.v.) injection
• Direct intratumoral (i.t.) injection
• Intraperitoneal (i.p.) injection

Altogen's In Vivo Transfection Reagent

• Forms siRNA-liposome and DNA-liposome complexes
• Cationic lipid liposome-based reagent
• Lipid conjugated siRNA- and DNA-complexes are stable in serum for 16h
• Efficient delivery to the liver, pancreas, kidney, and certain tumor types via systemic administration
• Efficient siRNA and plasmid DNA delivery via direct subcutaneous tumor injection (various tumor types)
• Minimal cytotoxicity
• Functionally tested in mice
• Applicable for plasmid DNA/siRNA co-injection
• Transfection protocols are provided with the purchase of the reagent
• Developed and manufactured by Altogen Biosystems

Data

Figure 1. Systemic administration (i.v.) of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).


Figure 2. Intratumoral administration (i.t.) of Lipid-based In Vivo reagent conjugated with siRNA targeting Lamin A/C mRNA or non-silencing control siRNA following the recommended protocol. Tissues were collected and RNA isolated 48 hours after first injection. Samples were analyzed by qRT-PCR for Lamin A/C gene expression levels. Ribosomal RNA levels were used to normalize the Lamin A/C data. Data are means ± SD (n=6).